India, Aug. 21 -- image credit- shutterstock

Thermo Fisher Scientific has announced plans to make significant investments in India's biopharma infrastructure, with new facilities that will enhance the biopharma manufacturing capabilities. The announcements came when senior executives addressed government, industry and academia at the Biopharma Conclave 2025, held in Hyderabad on 19 & 20 August.

In 2024, India's biopharmaceutical market was$8.1 billionin size, and is expected to almost double to$15.9 billionin 2030. Key drivers of this growth include increasing market maturity, forthcoming environment for regulatory approvals globally, and high-unmet clinical needs within India.

"India's biopharma sector is poised for a giant leap, and ...